Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

• Seroconversion rates for measles, mumps and rubella [ Time Frame: Approximately 42 to 56 days after the first vaccine dose ] [ Designated as safety issue: No ]
• Measles, mumps, rubella and varicella antibody titres [ Time Frame: 42 to 56 days after the first and second dose. ] [ Designated as safety issue: No ]
• Occurrence of solicited local symptoms [ Time Frame: Within 4 days (Day 0 - 3) after vaccination ] [ Designated as safety issue: No ]
• Occurrence of solicited general symptoms [ Time Frame: Within 43 days (Day 0 - 42) after vaccination ] [ Designated as safety issue: No ]
• Occurrence of unsolicited signs and symptoms [ Time Frame: Within 43 days (Day 0 - 42) after vaccination ] [ Designated as safety issue: No ]
• Occurrence of serious adverse events [ Time Frame: From Day 0 up to 42 to 56 days after the second dose ] [ Designated as safety issue: No ]

The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™ administered at 9 months of age followed by concomitant administration of Priorix™ with Varilrix™ at 15 months of age in a measles endemic environment such as India.

• Rubella
• Varicella
• Mumps
• Measles

• Biological: GSK Biological's investigational MMRV vaccine 208136
  Subcutaneous injection
• Biological: Priorix™
  Subcutaneous injection
• Biological: Varilrix™
  Subcutaneous injection

• Experimental: Group 1
  Subjects will receive GSK Biologicals' MMRV 208136 vaccine at 9 and 15 months
  Intervention: Biological: GSK Biological's investigational MMRV vaccine 208136
• Experimental: Group 2
  Subjects will receive Priorix™ at 9 months and GSK Biologicals' MMRV 208136 vaccine at 15 months
  Interventions:

  • Biological: GSK Biological's investigational MMRV vaccine 208136
  • Biological: Priorix™
• Active Comparator: Group 3
  Subjects in this group will receive Priorix™ at 9 months and Priorix™ + Varilrix™ at 15 months
  Interventions:

  • Biological: Priorix™
  • Biological: Varilrix™

Inclusion Criteria:

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• Male or female subjects between and including 9 and 10 months of age at the time of the first vaccination.
• Written informed consent obtained from the the parent or guardian of the subject.
• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• Planned administration/administration of a vaccine not foreseen by the study protocol starting 30 days prior to administration of any dose of the study vaccine, up to 42 days after the vaccine dose with the exception of hepatitis A vaccine and oral poliovirus vaccine .
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-registered product.
• Previous vaccination against measles, mumps, rubella and varicella.
• History of measles, mumps, rubella and/or varicella diseases.
• Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the start of the study.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• A family history of congenital or hereditary immunodeficiency.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccines including neomycin.
• Major congenital defects or serious chronic illness.
• History of any neurologic disorders or seizures.
• Acute disease at the time of enrolment.
• Axillary temperature > 37.5°C (99.5°F) / Rectal temperature > 38°C (100.4°F).
• Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.
• Presence of a susceptible high-risk person in the same household during the study period.